Cleft lip and/or palate (CLP) phenotypes are among the most frequent birth defects occurring at rates of 1/500--1/2500 births[@b1]. A proportion of cases present with syndromic disease (CLP in addition to a spectrum of additional phenotypes) mostly caused by rare mutations in single genes that often show Mendelian patterns of inheritance. However up to 70% of cases show phenotypes lacking any additional cognitive or craniofacial abnormalities, referred to as nonsyndromic cleft lip and/or palate (NSCLP). Such phenotypes are regarded as genetically complex arising through the interplay of numerous genetic and environmental factors. Increased understanding of the underlying aetiology of NSCLP phenotypes (both genetic and environmental) is needed to ultimately develop strategies for prevention, and improve treatment and prognosis. NSCLP has a significant genetic basis, for example, the first degree relatives of affected individuals have a 30--40 fold elevated risk and phenotype concordance for monozygotic (MZ) twins is 40--60%, compared to 5% for di-zygotic twins[@b1]. Genetic studies including linkage analysis, genome-wide association (GWAS), and GWAS-based meta-analysis, have yielded reproducible evidence for the involvement of several genes and gene regions. Collins *et al.*[@b2], listed 16 genes and gene regions which have been firmly implicated in NSCLP through linkage and association analysis. Several of these are broad regions where the underlying causal variant(s) have yet to be pinpointed, however, polymorphisms in genes such as *IRF6* are strongly associated with NSCLP[@b3] and more minor roles have been established for *MSX1*[@b4][@b5], *PVRL1*, *FGFR2*, *PAX7*, *NOG* and *SPRY2* among others[@b6].

Exome sequencing presents opportunities to identify rare coding variation that may contribute to risk of NSCLP phenotypes. If NSCLP is entirely multifactorial, the contribution of rarer variants may be largely polygenic and mediated by numerous variants of very small individual effect. In this case, causal genes may only be detectible through the analysis of large numbers of patients using, for example, burden tests[@b7]. However, there is growing evidence for involvement of rare variants of larger effect in NSCLP including, for example, truncating mutations in the *ARHGAP29* gene[@b8] and mutations in the *IRF6* gene, which is also known to contain mutations involved in malformation syndromes that include CLP such as Van der Woude[@b9]. We consider here a number of NSCLP families with multiple affected individuals and undertake exome sequencing to investigate the contribution of rare variants in genes previously associated with any form of clefting phenotype.

Materials and Methods
=====================

Exome sequences of twelve individuals from seven multi-case families (CL1-CL7) with NSCLP phenotypes were obtained. All experimental protocols were approved by the Research Ethics Committee at the Universidad de La Sabana, Bogota; informed consent was obtained for all participants and research was conducted in accordance with the Declaration of Helsinki. Families included between two and six individuals with isolated NSCLP ([Fig. 1](#f1){ref-type="fig"}). Most individuals have unilateral CLP but several individuals have the more severe bilateral phenotype.

DNA samples were extracted from blood collected at Operation Smile, Bogota, Colombia and exomes were captured using the Agilent SureSelect v5 (51 Mb) kit and sequenced on a HiSeq 2000. Read depth coverage statistics for all 12 exome sequences are given in [Supplementary Table 1](#S1){ref-type="supplementary-material"}, and indicate \~85--97% coverage of exon targets at \>20 fold depth across all samples. Orthogonal genotyping was performed for a panel of 24 SNPs to validate sample identity after processing[@b10].

To understand the spectrum of potentially damaging variation, we considered the list of 865 genes previously implicated in any form of CLP phenotype presented by Pengelly *et al.*[@b11] ([Supplementary Table 2](#S1){ref-type="supplementary-material"}). Examining rare variation in genes in this comprehensive list enables evaluation of whether known CLP genes contain variation which may underlie more familial forms of NSCLP. Furthermore, because each exome contains a very large number of putatively damaging variants including those completely unrelated to the clefting phenotypes (including potential incidental findings), this strategy focussing only on genes previously implicated in any form of clefting is a practical route to identifying causal variation in these families. The list is derived in part (363 genes out of the 865) from the professional Human Gene Mutation Database[@b12], using search terms related to clefts and clefting syndromes. The remaining genes in the list were included after corresponding interrogation of OMIM[@b13], and a small number of additional CLP-related genes from the review by Collins *et al.*[@b2].

We filtered the lists of variants ([Fig. 2](#f2){ref-type="fig"}) found in the exome sequences to identify all non-synonymous (NS), stopgain, stoploss, splicing and indel variants in genes from this list. Following Pengelly *et al.*[@b11], for NS variants we used the scaled predictive scores from dbNSFP v2[@b14] and considered only variants classed as deleterious or damaging by at least one of the following predictive metrics: PhyloP, SIFT, Polyphen2, LRT, MutationTaster and GERP++. Grantham scores were also assigned to all NS substitutions. All variants were annotated with the minor allele frequency (MAF) from the ExAC database[@b15], combined CADD and Logit scores for deleteriousness, along with a combined overall rank developed from PhylopP, GERP++, CADD and Logit scores based on the summed ranks across all four scores such that a variant with overall rank 1 is predicted as most deleterious. For intronic variants within 10 bp of the exon we utilised MaxEntScan, based upon quantifying deviation from the expected splicing consensus sequence motif, to evaluate the likelihood of this variant affecting splicing, using a cutoff of a differential score of 3[@b16].

We excluded variants found in homopolymer/repeat regions that can arise through misalignment between the sequenced reads and reference sequence. Any variants with read depth of \<10 or in genes considered to be 'highly mutable'[@b17] were removed from further consideration. We included all variants not previously listed in the following databases: dbSNP 135[@b18], 1000 genomes[@b19], the exome variant server[@b20] and our in-house database of \~300 exomes, but did not exclude variants present solely at low frequency in the ExAC database[@b15]. In [Tables 1](#t1){ref-type="table"} & [2](#t2){ref-type="table"} we included only variants found in all exome-sequenced, affected, family members but not shared by more than one family; this was to exclude variants potentially common to the region not captured in the population resequencing projects. Because samples were not available for all family members, it was not possible to confirm segregation of putatively causal variants for all affected individuals. All variants presented in text were manually visualised to evaluate genotype quality in the raw alignment files using IGV[@b21], and no features consistent with errors were present yielding high-confidence genotype calls. The full list of rare (\<1% in 1000 Genomes) NS variants classed as damaging by at least one predictive score and potentially damaging splicing variants are given in [Supplementary Table](#S1){ref-type="supplementary-material"}3. Whole-exome genotype calls are provided in [Supplementary File 4](#S1){ref-type="supplementary-material"}.

Results
=======

[Table 1](#t1){ref-type="table"} shows likely protein truncating and indel variants in these seven families, with [Table 2](#t2){ref-type="table"} listing 28 missense variants. For a given family only variants found for all the exome-sequenced family members ([Fig. 1](#f1){ref-type="fig"}) and classed as deleterious by at least one predictive score is given. [Table 2](#t2){ref-type="table"} entries are ordered using combined ranks from most to least deleterious by predictive score[@b11]. Four of the genes listed in [Table 2](#t2){ref-type="table"} (*WNT7A, MSX1, CLPTM1* and *EVC2*, ranked 9, 10, 11 and 23 respectively) have been previously identified as containing variants implicated in NSCLP phenotypes. Family CL1 has the 9^th^ ranked variant in the *WNT7A* gene. Members of the WNT gene family have previously been associated with NSCLP phenotypes[@b22][@b23][@b24]. Specifically, a number of WNT signalling pathway genes including *WNT3A, WNT5A, WNT9B*, and *WNT11* have been established as candidates[@b22] and mouse expression studies have shown roles for WNT genes in mid-facial formation and lip and palate development[@b25].

The 10^th^ ranked variant, found in family CL4, is in the *MSX1* gene, and considered damaging by SIFT, PolyPhen-2 and MutationTaster and has high GERP++ and CADD scores. Variants in this gene have been strongly implicated in NSCLP in several studies. Jezewski *et al.*[@b26] found mutations in 2% of CLP cases and indicated that this has genetic counselling implications where autosomal dominant inheritance patterns are found. Exon 2 of *MSX1,* in which the p.P260T is located, has been found to be highly conserved with significantly fewer sequence variants compared with exon 1 of this small (two exon) gene[@b26]. Functional validation of *MSX1* as a candidate is established through a cleft palate and foreshortened maxilla phenotype in knockout mice[@b27]. A number of association studies have also indicated involvement of *MSX1* in NSCLP[@b4][@b28][@b29][@b30][@b31]. In a study of 94 patients and 93 controls from Operation Smile, Colombia, four *MSX1* microsatellite alleles were analysed and an increased risk of CLP was observed with CA polymorphisms in the gene[@b32]. An autosomal dominant *MSX1* mutation in a family with clefting and tooth agenesis showed a familial pattern of segregating *MSX1* mutations[@b5]. Diverse evidence establishes that *MSX1* promotes growth and inhibits differentiation. Mutations in *MSX1* can cause primary or secondary facial clefting in mouse models[@b26].

The 11^th^ ranked variant (from family CL1) is in the *CLPTM1* gene (Cleft lip-and palate-associated transmembrane protein-1) which is situated at 19q13.3. A balanced translocation is this region was found in a multi-case CLP family[@b33] and this region is implicated in NSCLP by linkage and transmission disequilibrium test association studies[@b34]. However a *de novo* deletion of 0.8 Mb in this region associated with CLP, but not encompassing *CLPTM1,* has been reported[@b35]. As Kohli and Kohli[@b36] indicate, the role of *CLPTM1* or other genes in this locus is uncertain.

The 23^rd^ ranked variant is in the *EVC2* gene (family CL2) and belongs to the same two megabase chromosomal region as *MSX1* (4p16). Ingersoll *et al.*[@b37] found linkage and association signals in genes in this region. They found suggestive evidence for linkage and association amongst cleft palate trios to *EVC2*. Mutations in *EVC2* can lead to Weyers acrofacial dysostosis[@b38], not usually associated with oral clefts but cases with subtle CLP phenotypes, and tooth anomalies have been reported[@b37].

Discussion
==========

Linkage, candidate gene association and genome-wide association (GWAS) have been applied to investigate numerous multifactorial diseases, including NSCLP. As a result of these studies more than 11 genes and gene regions are now known or likely to have an etiologic role in NSCLP[@b39]. However, there is increasing evidence that NSCLP is a heterogeneous condition comprising a substantial multifactorial component along with a much smaller proportion of cases showing more Mendelian patterns of inheritance. The Gajdos *et al.*[@b40] segregation analysis indicated that the complex familial patterns observed in NSCLP is best explained as a mixture of monogenic cases, probably dominantly inherited, combined with others which have a multifactorial aetiology. The conclusions favour analyses of multiple-case pedigrees to reduce heterogeneity and help identify Mendelian sub-forms. Stanier and Moore[@b41] identified significant overlaps between genes underlying syndromic and nonsyndromic forms of CLP, recognising that several genes implicated in syndromic disease, including *TBX22, PVRL1, IRF6, P63* and *MSX1*, can also contribute to \~10% of NSCLP. Scapoli *et al.*[@b42] point out that the autosomal dominant Van der Woude syndrome (VWS) is only phenotypically distinguished from NSCLP by lower-lip pits and hypodontia which are only variably present in VWS affected individuals. Mutations in the *IRF6* gene, which cause VWS, have been firmly implicated in some NSCLP cases[@b3] supporting heterogeneity with the NSCLP clinical designation. Furthermore, Kerameddin *et al.*[@b43] found a tag SNP (rs642961) in *IRF6* was associated with the most severe complete bilateral NSCLP phenotype. This suggests multi-case families with bilateral clefts are the most likely to be segregating single gene mutations. This strategy is supported by Vieira *et al.*[@b44] who indicate that point mutations in several genes contribute to \~6% of NSCLP, and these are enriched in cases with bilateral clefting.

In [Table 2](#t2){ref-type="table"}, we identify a coding variant in the *MSX1* gene shared by affected family members in CL4 in which the proband has a bilateral CLP phenotype. Direct sequencing of coding regions has shown rare mutations in *MSX1* may account for \~2% of NSCLP. The identified *MSX1* variant is present at low frequency in the ExAC database ([Table 2](#t2){ref-type="table"}). ExAC contains \>60,000 exomes from various disease specfic and population genetic studies (<http://exac.broadinstitute.org/>). Functional studies and analyses of larger cohorts of multi-case NSCLP families are required to establish a possible role for this and other rare variants identified in NSCLP phenotypes. Variants identified here also include candidates in the *WNT7A* (family CL1) *,CLPTM1* (family CL1) and *EVC2* genes (family CL2) which should be considered as targets for analysis in additional families.

For investigations aiming to resolve the genetic factors underlying NSCLP in multiple case families, exome sequencing presents a relatively cost-effective approach in which sequencing a small number of affected family members can identify candidate underlying genetic variation. NSCLP provides a particular challenge for genetic studies, with incomplete penetrance and environmental factors hindering the identification of aetiological variance[@b2][@b39]. We have aimed to minimise this effect by careful selection of pedigrees exhibiting clefting in multiple individuals, where we would expect a stronger genetic component. Filtering power would be increased by the inclusion of further members of the pedigrees, however this has not been viable due to the isolated geographic locations for many individuals.

Exome sequencing yields thousands of variants per individual and identification of candidate variants can only be achieved following extensive filtering. We have undertaken filtering to identify variants predicted as damaging by restricting analysis to a list of 865 genes which have been previously associated with any condition involving CLP. Such an approach risks missing causal variants in novel genes not previously linked to NSCLP, but facilitates practicable data interpretation by virtue of the greater prior probability that they are associated with NSCLP. The composite score based rank using PhyloP, GERP++. CADD and logit ([Table 2](#t2){ref-type="table"}) has been used successfully prioritise variants involved in syndromic CLP[@b11], These four scores are closely correlated, although the composite measures are not independent in every case. Further improvements in predictive tools and recognition of more disease variants and understanding of disease pathways will enable future improvements in interpretation of these complex data sets.

Whilst predictive tools are essential for the prioritisation of variants discovered in next generation sequencing (NGS) studies, ultimately functional validation of the effects of variants on protein function is required to confirm their impact. Given the volume of potentially pathogenic variants being identified in NGS studies, routine functional validation is infeasible. *In silico* protein modelling approaches may also be used to improve throughput, however these require the prior determination of protein structure, which has not been reported in the majority of genes discussed herein. Overall, it is clear that functional validation is a significant bottleneck in NGS studies, and one not readily assuaged.

The limitations of exome sequencing include lack of coverage outside gene coding regions thereby excluding regulatory variants, which may influence risk. Technical limitations include poor coverage of some coding regions thereby missing potential causal variants. Whole genome sequencing offers a solution to these coverage issues, but at higher cost and considerably increased analytical complexity. Given the extent of the missing heritability in CLP, it is likely non-coding regions of the genome play a significant role; whole genome sequencing may therefore provide a valuable tool as sequencing costs continue to drop.

In this study we have limited our analyses to 865 genes with a known/suspected involvement in CLP phenotypes. Whilst this will prevent us from identifying novel aetiological genes, 7 families would be underpowered to identify novel causal genes reliably. Large cohort studies are required in order to identify novel CLP genes; to this end we have made our WES data available in [Supplementary File 4](#S1){ref-type="supplementary-material"} for the use of other researchers.

In conclusion, we have undertaken exome analysis in seven Colombian families with NSCLP phenotypes. We find a deleterious variant in the *MSX1* gene in family CL4 which is a strong candidate for causality. Deleterious variants in at least three additional genes may be implicated in NSCLP phenotypes in some of the other families. Although NSCLP is primarily a complex multifactorial phenotype, our study adds to the growing body of evidence that Mendelian sub-forms exist and these are best studied in multi-case families particularly where there are more severe phenotypic features such as bilateral clefting.
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###### Protein truncating, splicing and indel variants observed in single families.

  Gene       Genomic Position   Transcript ID   Exon        mRNA change        Protein change         Variant type         ExAC MAF   ΔMaxEnt   CL1   CL2   CL3   CL4   CL5   CL6   CL7
  --------- ------------------ --------------- ------ ----------------------- ----------------- ------------------------- ---------- --------- ----- ----- ----- ----- ----- ----- -----
  *DLG1*       3:196846393      NM_001204388     8          923_925del           308_309del      nonframeshift_deletion       \-         .                         ◊                  
  *FRAS1*       4:79391228        NM_025074      51           G7354T               E2452X               stopgain              \-         .                                     ◊      
  *WDR11*      10:122660583       NM_018117      21        2660_2662del          887_888del      nonframeshift_deletion       \-         .                   ◊                        
  *IGF1R*      15:99500507        NM_000875      21    3940_3941insCGTCCTCCC   L1314delinsPSSL   nonframeshift_insertion      \-         .       ◊                                    
  *FBLN1*      22:45927140        NM_001996      5           485-5C\>-                                  splicing              \-        22       ◊                                    

◊ = Heterozygous variant observed for all family members sequenced.

###### Non-synonymous variants observed in single families.

  Gene         Genomic Position   Transcript ID   Exon   mRNA change   Protein change   ExAC MAF      SIFT       PolyPhen-2    MutationTaster   Grantham score   PhyloP   GERP++   CADD    Logit   Rank   CL1   CL2   CL3   CL4   CL5   CL6   CL7
  ----------- ------------------ --------------- ------ ------------- ---------------- ---------- ------------- ------------- ---------------- ---------------- -------- -------- ------- ------- ------ ----- ----- ----- ----- ----- ----- -----
  *WDR35*         2:20137643      NM_001006657     20      C2161T          R721C        4.1E-05    [0.00]{.ul}   [0.92]{.ul}    [1.00]{.ul}       [180]{.ul}      9.81     5.04    27.70   0.13     1      ◊                                    
  *PTHLH*        12:28122357        NM_002820      3        G71A            G24E           \-      [0.00]{.ul}   [1.00]{.ul}    [0.99]{.ul}           98          5.75     5.13    32.00   0.39     2            ◊                              
  *GPC6*         13:94482686        NM_005708      3        T599A          F200Y           \-      [0.00]{.ul}   [0.98]{.ul}    [0.95]{.ul}           22          7.65     5.48    31.00   0.06     3      ◊                                    
  *INPPL1*       11:71939494        NM_001567      3        G349A          V117I           \-      [0.00]{.ul}   [0.95]{.ul}        0.04              29          8.18     3.90    22.80   0.11     4      ◊                                    
  *MYH3*         17:10539158        NM_002470      29      G3869A          R1290H       3.3E-05    [0.00]{.ul}      0.10            0.94              29          4.95     4.84    21.30   0.13     5                        ◊                  
  *AHDC1*         1:27876631      NM_001029882     6       C1996G          R666G        8.6E-06    [0.00]{.ul}   [1.00]{.ul}        0.06          [125]{.ul}      8.73     5.08    22.80   0.04     6            ◊                              
  *ABCA12*       2:215928852        NM_173076      3        C254T           T85I           \-         0.99       [0.73]{.ul}        0.00              89          4.18     5.30    15.26   0.10     7                  ◊                        
  *DEAF1*         11:654023         NM_021008      11      C1532G          A511G           \-      [0.00]{.ul}   [0.59]{.ul}    [1.00]{.ul}           60          9.01     3.03    17.71   0.08     8                  ◊                        
  *WNT7A*         3:13860472        NM_004625      4       G1019A          S340N           \-      [0.00]{.ul}   [0.94]{.ul}    [0.99]{.ul}           46          6.07     4.11    23.60   0.06     9      ◊                                    
  *MSX1*          4:4864736         NM_002448      2        C778A          P260T        1.3E-04    [0.00]{.ul}   [0.61]{.ul}    [0.99]{.ul}           38          5.96     4.76    27.60   0.04     10                       ◊                  
  *CLPTM1*       19:45491357        NM_001294      9       A1058G          N353S        8.2E-06    [0.04]{.ul}   [0.60]{.ul}    [0.99]{.ul}           46          6.60     3.01    17.19   0.09     11     ◊                                    
  *IGF1R*        15:99500597        NM_000875      21      C4030G          Q1344E          \-      [0.00]{.ul}      0.01        [0.99]{.ul}           29          4.78     5.24    13.05   0.04     12     ◊                                    
  *CFDP1*        16:75429103        NM_006324      5        A535T          T179S           \-      [0.00]{.ul}      0.02        [0.99]{.ul}           58          2.66     5.54    15.68   0.04     13     ◊                                    
  *NBAS*          2:15651437        NM_015909      10       G784A          G262S           \-      [0.01]{.ul}      0.09            0.86              56          4.26     4.15    13.81   0.07     14     ◊                                    
  *COL17A1*      10:105795306       NM_000494      49      T3434C          I1145T       1.9E-05    [0.00]{.ul}      0.15            0.31              89          5.46     4.39    12.18   0.06     15                             ◊            
  *CDON*         11:125887051     NM_001243597     6        A860G          N287S           \-      [0.00]{.ul}      0.34            0.64              46          3.10     5.01    15.32   0.04     16                                         ◊
  *SNAP29*       22:21224814        NM_004782      2        A427G          N143D           \-      [0.02]{.ul}      0.34            0.17              23          8.77     3.70    11.41   0.04     17           ◊                              
  *NOTCH2*       1:120509101      NM_001200001     9       G1465T          V489L           \-      [0.00]{.ul}      0.08            0.34              32          0.87     5.38    12.51   0.05     18                       ◊                  
  *MASP1*        3:186937872        NM_001879      16      G2087A          G696E        1.7E-05    [0.05]{.ul}      0.09            0.37              98          1.65     3.75    14.53   0.06     19                                   ◊      
  *FREM2*        13:39263993        NM_207361      1       A2512G          T838A        8.2E-06    [0.00]{.ul}      0.00        [1.00]{.ul}           58          2.49     4.44    7.38    0.07     20                       ◊                  
  *SPRY4*        5:141693887        NM_030964      3        C856T          R286C        2.5E-05    [0.00]{.ul}   [0.88]{.ul}    [0.97]{.ul}       [180]{.ul}      2.44     4.70    13.49   0.04     21                 ◊                        
  *ZBTB24*       6:109802863      NM_001164313     2        A367G          K123E           \-      [0.00]{.ul}      0.05            0.32              56          1.52     4.16    14.67   0.03     22                       ◊                  
  *EVC2*          4:5617202       NM_001166136     16      G2536A          E846K        1.6E-05       0.10       [0.67]{.ul}        0.27              56          1.14     2.85    16.13   0.03     23           ◊                              
  *SCN2A*        2:166187894      NM_001040143     13      T2204C          M735T           \-      [0.04]{.ul}      0.00            0.06              81          0.47     2.35    2.95    0.04     24                 ◊                        
  *RYR1*         19:38976754        NM_000540      34      G5459T          R1820L          \-      [0.04]{.ul}      0.01            0.71          [102]{.ul}      0.93     1.71    8.87    0.03     25                             ◊            
  *WT1*          11:32456755        NM_024426      1        C137T           A46V           \-      [0.02]{.ul}      0.00            0.00              64          0.33     0.81    12.21   0.02     26                       ◊                  
  *INPPL1*       11:71949096        NM_001567      27      T3563G          L1188R       1.0E-05       0.10            .             0.01          [102]{.ul}      0.44     1.47    10.20   0.01     27     ◊                                    
  *COL6A2*       21:47551876        NM_001849      28      G2470A          V824M        2.9E-04    [0.00]{.ul}        .         [1.00]{.ul}           21           .       3.62      .       .      \-                             ◊            

◊ = Heterozygous variant observed for all family members sequenced.

Underlined predictive scores damaging by at least one of: SIFT \<0.05 (variant considered to affect protein function); PolyPhen-2 HumVar scores \>0.447 (variant possibly damaging) and \> = 0.909 (variant probably damaging); MutationTaster scores \>0.95 (variant considered damaging); Grantham scores \>100 (radical amino acid change).
